UK MHRA to pilot risk-based approach for authorising clinical trials
This article was originally published in SRA
The UK Medicines and Healthcare products Regulatory Agency is gearing up to launch a pilot project to assess the use of a risk-based approach for authorising clinical trials.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.